ARTICLE | Clinical News
Zevalin ibritumomab tiuxetan regulatory update
January 8, 2001 8:00 AM UTC
The FDA accepted for filing IDPH's BLA for Zevalin radiolabeled antibody to treat low grade or follicular, relapsed or refractory, CD20-positive, B cell non-Hodgkin's lymphoma (NHL), and follicular NH...